Monday, June 18, 2012
Oxygen Biotherapeutics Inc., of Morrisville, N.C., said it entered agreements with institutional investors to amend the terms of its $7.5 million offering of registered shares of Series A convertible preferred stock and registered warrants to purchase shares.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.